Merck (MRK) earnings Q3 2026

Key Points:

• Merck surpassed third-quarter earnings expectations with adjusted earnings per share of $2.49, beating the $2.08 expected, and reported revenue of $18.09 billion, exceeding the $17.31 billion forecast.
• The company raised its adjusted profit outlook to $2.77-$2.82 per share, up from $2.66-$2.76, despite including a $400 million one-time charge related to a licensing deal with Chinese firm SciBrunch.
• Keytruda sales reached $8.60 billion for the quarter, significantly outperforming analyst estimates, with the newer injectable form, Keytruda Qlex, generating $830 million in sales and becoming a key part of Merck’s growth strategy.
• Other products like Winrevair and the Gardasil vaccine also showed strong sales growth, with Winrevair sales up 93% year-over-year to $694 million and Gardasil sales hitting about $2 billion driven by higher U.S. demand.
• Merck narrowed its 2026 revenue guidance to $66.8 billion-$67.3 billion and continues to pursue acquisitions to offset expected generic competition for Keytruda after its patents expire in 2028.